Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 booster study of CSL402-XEC self-amplifying mRNA COVID-19 vaccine
jRCT2031250317Phase 3Active, not recruiting
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of CSL402-XEC in coronavirus disease 2019 (COVID-19) (5 cohorts), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Geometric mean titer of neutralizing antibodies against SARS-CoV-2 (Omicron XEC) on Day 29. Started Sep 2025; status: active, not recruiting.
02
Drugs
CSL402-XEC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031250317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250317.